Pink eye, also known as conjunctivitis, is a common and highly contagious eye infection characterized by inflammation of the conjunctiva – the thin, clear tissue that lines the inside of the eyelid and covers the whites of the eyes. This condition earns its name due to the telltale symptom it presents: reddish or pink discoloration in one or both eyes. Pink eye can be caused by several factors including bacterial or viral infections, allergies, irritants like smoke or chemicals, and even certain sexually transmitted diseases. Regardless of its origins, pink eye typically manifests with uncomfortable symptoms such as itching, burning sensations, excessive tearing, or discharge which may lead to crusting around the eyes. While proper hygiene practices such as handwashing and avoiding touching your face can help prevent this ailment from spreading further among individuals in close proximity – particularly in places like schools or offices where transmission is swift – timely medical intervention remains crucial to alleviate discomfort and prevent prolonged recuperation periods associated with this common ocular affliction.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation